WO2022125007A1 - Prolonged release mirabegron formulations - Google Patents
Prolonged release mirabegron formulations Download PDFInfo
- Publication number
- WO2022125007A1 WO2022125007A1 PCT/TR2020/051260 TR2020051260W WO2022125007A1 WO 2022125007 A1 WO2022125007 A1 WO 2022125007A1 TR 2020051260 W TR2020051260 W TR 2020051260W WO 2022125007 A1 WO2022125007 A1 WO 2022125007A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- mirabegron
- prolonged release
- solid pharmaceutical
- release solid
- Prior art date
Links
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 title claims abstract description 55
- 229960001551 mirabegron Drugs 0.000 title claims abstract description 52
- 230000002035 prolonged effect Effects 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000009472 formulation Methods 0.000 title abstract description 7
- 239000004014 plasticizer Substances 0.000 claims abstract description 17
- 229920001600 hydrophobic polymer Polymers 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 239000007787 solid Substances 0.000 claims description 16
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 14
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 14
- 208000020629 overactive bladder Diseases 0.000 claims description 14
- 239000001856 Ethyl cellulose Substances 0.000 claims description 12
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 6
- 239000001069 triethyl citrate Substances 0.000 claims description 6
- 235000013769 triethyl citrate Nutrition 0.000 claims description 6
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000005550 wet granulation Methods 0.000 claims description 6
- 206010027566 Micturition urgency Diseases 0.000 claims description 5
- 206010036018 Pollakiuria Diseases 0.000 claims description 5
- 239000007888 film coating Substances 0.000 claims description 5
- 238000009501 film coating Methods 0.000 claims description 5
- 239000010410 layer Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 208000022934 urinary frequency Diseases 0.000 claims description 5
- 230000036318 urination frequency Effects 0.000 claims description 5
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 4
- -1 polyethylene Polymers 0.000 claims description 4
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 239000004800 polyvinyl chloride Substances 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 239000008199 coating composition Substances 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000003826 tablet Substances 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- 101000780539 Homo sapiens Beta-3 adrenergic receptor Proteins 0.000 description 1
- 101100189057 Homo sapiens SLC10A3 gene Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HIKIGWCXRDSDRC-UHFFFAOYSA-L disodium (E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].C(C=CC(=O)[O-])(=O)OCCCCCCCCCCCCCCCCCC.[Na+].C(CCCCCCCCCCCCCCCCC)OC(C=CC(=O)[O-])=O HIKIGWCXRDSDRC-UHFFFAOYSA-L 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 229940093500 ethoxyquin Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007912 modified release tablet Substances 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940120393 myrbetriq Drugs 0.000 description 1
- HWMFFWCDLWDYGX-UHFFFAOYSA-N n-(4-aminophenyl)furan-2-carboxamide Chemical compound C1=CC(N)=CC=C1NC(=O)C1=CC=CO1 HWMFFWCDLWDYGX-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 239000002491 polymer binding agent Substances 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960001187 propiverine hydrochloride Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Definitions
- the present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient in which release profile of the active ingredient is controlled by using a specific hydrophobic polymer and a plasticizer at a specific range of ratio in the coating formulation.
- Overactive bladder is defined by The International Continence as urgency, with or without urgency incontinence, usually with frequency and nocturia. There is lack of information why overactive bladder occurs, but it is known that it involves detrusor overactivity which is responsible for feeling urgency by involving afferent signaling conveyed as bladder sensations.
- overactive bladder There are many options for treatment of overactive bladder such as; bladder training and drug therapy using anticholinergic substances such as propiverine hydrochloride and oxybutynin hydrochloride have been mostly used at present. However, intractable cases and side effects could be occurred such as urinary dysfunction and dry mouth and, therefore, Mirabegron has been reported as one of the substance for the management of overactive bladder.
- Mirabegron is a selective agonist for human beta 3 -adrenoceptor (beta 3 -AR) which is also dominant in the human detrusor muscle.
- Beta 3 -AR human beta 3 -adrenoceptor
- Mirabegron has been firstly declared by the Astellas Pharma Inc to be used for the treatment for diabetes, due to having an activity of promoting insulin secretion and enhancing insulin sensitivity, and also having an antiobestic activity and an antihyperlipemic activity.
- Mirabegron can be used as an overactive bladder, such as overactive bladder accompanied by prostatic hyperplasia, or overactive bladder accompanied by urinary urgency, urinary incontinence, and urinary frequency.
- Mirabegron is 2-(2-Amino-l,3-thiazoI-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy- 2-phenylethyl] amino ⁇ ethyl )phenyl] acetamide and the empirical formula is C2JH24N4O2S.
- the compound has a molecular weight of 396.506 g/mol.
- the structural formula of Mirabegron is shown in the Formula I.
- Mirabegron appears as a white crystalline powder and non-hygroscopic. It can freely soluble in dimethyl sulfoxide, soluble in methanol and soluble in water between neutral to acidic pH, thus it is categorized as BCS III Drug which means that Mirabegron exhibits high solubility and low permeability.
- Mirabegron has one chiral center and exhibits stereoisomerism.
- the manufacture of the finish product consists of the R-enantiomer.
- Mirabegron and its pharmaceutically acceptable salts thereof first have been described in EP1028111 numbered patent document by Yamanouchi Pharmaceutical Co. for the treatment of the Diabetes Mellitus.
- Example 41 discloses the preparation of mirabegron and its pharmaceutically acceptable salt thereof, with hydrochloride salt.
- patent document numbered as EP1559427 was first disclosed a pharmaceutical composition comprising mirabegron that can be used as a therapeutic agent for overactive bladder, such as overactive bladder accompanied by prostatic hyperplasia, or overactive bladder accompanied by urinary urgency, urinary incontinence, and urinary frequency.
- the marketed product contains R-enantiomer of mirabegron was first described in patent document numbered as EP2298752, wherein an a-form crystal of mirabegron R- enantiomer has a moisture holding amount of not more than 0.2% and has main peaks at around 5.32, 8.08, 15.28, 17.88, 19.04, 20.20, 23.16 and 24.34 in the terms of 29(°) in the powder X- ray diffraction.
- Mirabegron is in the prolonged released film coated tablet dosage form to control the drug release from the tablet which lead to more slower absorption rate in the gastrointestinal tract than immediate release formulations, even in fasted conditions, due to pharmacokinetic variation of mirabegron according to the presence or absence of food intake.
- the rate of decrease in Cmax and AUC is 45% and 17%, respectively, when there is a coadministration with high fat meal.
- that decreasing is not higher when there is a coadministration with low fat meal which decreased Mirabegron Cmax and AUC by 75% and 51%, respectively.
- EP2554168 relates to a pharmaceutical composition for modified release comprising mirabegron or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein the dissolution rate of the drug from the composition is 75% or less after 1.5 hours from the beginning of the dissolution test, and also wherein the pharmaceutical composition is not a sustained release hydrogel formulation which contains an additive that allows water to penetrate into the formulation, and a hydrogel-forming polymer.
- EP2345410 relates to a pharmaceutical composition for modified release comprising mirabegron, at least one additive having a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less to ensure penetration of water into the pharmaceutical composition, and a hydrogel-forming polymer having an average molecular weight of approximately 100.000 or more, or a viscosity of 12 mPa.s or more at a 5% aqueous solution at 25°C.
- EP3278801 relates to a pharmaceutical composition
- a pharmaceutical composition comprising a complex of mirabegron with sodium polystyrene sulfonate, a thickener, and a hydrophobic substance, wherein the hydrophobic substance is magnesium stearate and/or calcium stearate.
- EP2832730 relates to a pharmaceutical composition for modified release comprising mirabegron dodecyl sulfate wherein a molar ratio of Mirabegron to alkyl sulfuric acid is 1 : 1 to 1:2.
- WO201 1122523 relates to a pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, and the drug dissolution rate after 30 minutes from the beginning of the dissolution test is less than 85%.
- EP3345600 relates to a pharmaceutical composition
- a pharmaceutical composition comprising mirabegron, hypromellose, and polyvinylpyrrolidone, wherein the spray-dried granulated product contains 100% or more by mass of the hypromellose, and the polyvinylpyrrolidone in total with respect to a content of the mirabegron.
- W02019072404 relates to a pharmaceutical composition for modified release comprising; mirabegron presenting 5-25 wt% to the total weight of the uncoated tablet, polyethylene oxide having an average molecular weight of approximately 7,000,000 or a viscosity of 7500 to 10000 cps at a 1% aqueous solution at 25°C and polyethylene glycol having an average molecular weight of approximately 6000 to 10000, preferably 8000, wherein the weight ratio polyethylene oxide to polyethylene glycol ranges from 1:3 to 1:4.5;
- EP3448366 relates to a pharmaceutical composition for modified release comprising; 5 to 25 wt%, relative to the total weight of mirabegron, 15 to 40 wt%, relative to the total weight, of a mixture of one or more polyethylene oxides having a viscosity of 100 to 800, preferably 400 to 800 cP at a 2% aqueous solution at 25°C, and a water insoluble hydrophilic excipient.
- EP3554480 relates to a solid prolonged release solid pharmaceutical oral dosage form comprising mirabegron or a pharmaceutically acceptable salt thereof wherein Mirabegron is distributed in a sustained release matrix comprising a hydrogel generator selected from the group consisting of a mixture of at least two different hydroxypropyl methylcellulose, of alginate, alginic acid, poly (meth) acrylate -based polymer and carrageenan, and wherein dissolution rate of the drug from the composition is 20% to 40% in 3 hours, 44% to 64% in 5 hours and more than 80% in 8.5 h.
- a hydrogel generator selected from the group consisting of a mixture of at least two different hydroxypropyl methylcellulose, of alginate, alginic acid, poly (meth) acrylate -based polymer and carrageenan, and wherein dissolution rate of the drug from the composition is 20% to 40% in 3 hours, 44% to 64% in 5 hours and more than 80% in 8.5 h.
- WO2018169325 relates to a controlled release pharmaceutical composition
- a controlled release pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof and a polyethylene oxide as a sustained release agent.
- the prepared pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient in a prolonged release profile by using a hydrophobic polymer with a plasticizer in a range ratio of 1:0.5 - 1:1 in the film coating layer.
- the object of this invention is to develop a prolonged release solid pharmaceutical composition
- a prolonged release solid pharmaceutical composition comprising a therapeutically effective amount of mirabegron or one of its pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient.
- It is an object of the present invention is to develop a prolonged release solid pharmaceutical composition comprising mirabegron or one of its pharmaceutically acceptable salts, which is used in the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
- the present invention is to develop a prolonged release solid composition comprising mirabegron and at least one pharmaceutically acceptable excipient manufactured by using wet granulation process.
- Another object of the present invention is to develop preparation method of a pharmaceutical composition of Mirabegron wherein the pharmaceutical compositions herein disclosed can be manufactured into solid dosage forms, such as tablet, capsule, granule, powder.
- Another object of the present invention is related to a pharmaceutical composition
- a pharmaceutical composition comprising mirabegron and at least one pharmaceutically acceptable excipient and a functional film coating including a hydrophobic polymer and a plasticizer.
- Another object of the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a hydrophobic polymer and a plasticizer in a range ratio of 1:0.5 - 1:1 in the coating film layer to provide prolonged release of mirabegron throughout the entire gastrointestinal tract.
- the present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient.
- Mirabegron is a human P3 -adrenoceptor agonist which has been used for the management of overactive bladder syndrome for decades. Mirabegron exhibits high solubility and low permeability. Thus, after oral administration it is rapidly absorbed, but its absolute bioavailability is low and it slightly increased 29% at a 25 mg dose and 35% at a 50 mg dose. Besides that, there is another restriction about its bioavailability when given with food or absence of food throughout gastrointestinal tract.
- a pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof, wherein the variation in bioavailability caused by the presence or absence of food intake throughout gastrointestinal tract is minimized by controlling the drug release.
- the composition comprising mirabegron or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient is presented as prolonged release tablet dosage form.
- Prolonged release refers to any composition or dosage form which comprises active ingredient and which is formulated to provide a longer duration of pharmacological response after administration of the dosage form than is ordinarily experienced after administration of a corresponding immediate release composition comprising the same drug in the same amount.
- Prolonged release is a continuous release of the active ingredient in a period of time of greater than about 1 hour, preferably greater than about 4 hours, more preferably, greater than about 8 hours.
- the term “prolonged release” can be conveniently replaced by similar terms like modified release, controlled release, timed release, retarded release, extended release and delayed release, sustained release, programmed release and/or rate controlled dosage forms.
- Suitable solid oral dosage forms are selected from the group comprising tablet, capsule, granule, powder, preferably the solid oral dosage form is tablet.
- a hydrophobic polymer is designated for continuous drug release in the human gastrointestinal tract with diffusion of dissolving drug through a network of channels that exist between compacted polymer particles.
- the hydrophobic polymer may include, but are not limited to, polyethylene, polyvinyl chloride, ethyl cellulose and acrylate polymers and their copolymers.
- the hydrophobic polymer is selected as ethyl cellulose.
- ethyl cellulose In the development dosage forms with modified release, ethyl cellulose is the perfect polymer to ensure drug dissolution throughout gastrointestinal tract and provide constant drug concentration. As the mechanism of action of ethyl cellulose, being insoluble at any gastrointestinal fluid at any pH, it undergoes to swell in these environments. As a result, it plays a significant role to improve the therapeutic effectiveness. In the present invention, it is used to provide the release of a drug in a controlled manner by using as an agent in coating formulation.
- Ethyl cellulose is a biocompatible, non-allergenic, nonirritant, colorless, odorless, and tasteless hydrophobic polymer soluble in a wide variety of organic solvents such as alcohols, ketones, and polycyclic aromatic hydrocarbons, or solvent mixture to produce water insoluble films, but it does not dissolve in water, glycerin, or propylene glycol.
- Ethyl cellulose effect can be modified by using in combination with a proper plasticizer in a specific ratio. Moreover, wherein plasticizer molecules are built in amongst the polymer chains that may cause to shift along each other in order to increasing the elasticity of the polymer film.
- the compatibility between the excipients is quite important in order to reduce potential reduction between excipients which may affect the chemical, physical, bioavailability and stability of the dosage form.
- ethyl cellulose is known to be quite compatible polymer with a wide array of excipients and most of the plasticizer.
- the plasticizer may include, but are not limited triethyl citrate, acetyltriethyl citrate, tributyl citrate, and acetyltributyl citrate and the like and mixtures thereof.
- the plasticizer is selected as triethyl citrate.
- compositions comprising Mirabegron by using wet granulation process wherein provided for the manufacture of tablets containing the active ingredient, hydrophobic polymer binder, antioxidant, plasticizer, glidant and lubricant and solvent selected as to be the most suitable ones with respect to the intended form of administration.
- the binder may include, but are not limited to dibasic calcium phosphate dihydrate, polysaccharides, microcrystalline cellulose, lactose and the like and mixtures thereof.
- the binder is microcrystalline cellulose.
- the antioxidant may include, but are not limited to butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate, sodium sulfite, sodium thiosulfate, monothioglycerol, tert-butyl hydroquinone, ethoxyquin, dithiothreitol, and derivatives thereof.
- the antioxidant is butylated hydroxy toluene.
- the lubricant may include, but are not limited to magnesium stearate, zinc stearate, calcium stearate, talc, carnauba wax, stearic acid, sodium stearyl fumarate sodium laurel sulfate, glyceryl palmitostearate, and hydrogenated vegetable oils and fats, as well as other known lubricants.
- the lubricant is magnesium stearate.
- the glidant may include, but are not limited to silicon dioxide, colloidal silicon dioxide, magnesium silicate, magnesium trisilicate, talc and other known glidant.
- the glidant is colloidal silicon dioxide.
- the solvent may include, but are not limited deionized water, methanol, ethanol, isopropyl alcohol, dichloromethane, acetone, ethyl acetate, dimethylsulfoxide and their mixtures thereof.
- the solvent is deionized water.
- the embodiment in accordance with the present invention was designed with adjusted quantitative composition composed of pharmaceutically acceptable ingredients mentioned above by using wet granulation process.
- Example 1 The embodiment identified as Example 1 was given in the Table- 1 below.
- Another object of the present invention relates to provide wet granulation process for preparing a prolonged release pharmaceutical composition, providing the steps of: i. Mirabegron, Microcrystalline cellulose and Butylated hydroxytoluene were screened through a proper sieve and transferred into high-shear mixer and stirred, ii. Ethyl cellulose was dissolved in sufficient quantity of deionized water and added to the preparation in Step i to perform granulation process, iii. The granules prepared in Step ii were dried in fluid bed dryer and shifted through a proper sieve, iv. Colloidal silicon dioxide was screened through a proper sieve and added to the granules prepared in Step iii and stirred, v.
- Magnesium stearate was screened through a proper sieve and added to the granules prepared in Step iv and stirred to obtain a uniform final blend, vi. Tablet compression was performed with the final blend in Step v. vii.
- the coating was formulated separately including 1:0.5 - 1:1 ratio of ethyl cellulose and triethyl citrate, then it was applied to tablets prepared in Step vi.
- the coating film layer is applied after the core tablet is prepared by using wet granulation process wherein the coating consists of ethyl cellulose as a hydrophobic polymer which is insoluble in water and gastro-intestinal fluids and triethyl citrate as a plasticizer in the ratio of
Abstract
The present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient in which release profile of the active ingredient is controlled by using a specific hydrophobic polymer and a plasticizer at a specific range of ratio in the coating formulation.
Description
PROLONGED RELEASE MIRABEGRON FORMULATIONS
FIELD OF INVENTION
The present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient in which release profile of the active ingredient is controlled by using a specific hydrophobic polymer and a plasticizer at a specific range of ratio in the coating formulation.
BACKGROUND OF THE INVENTION
Overactive bladder is defined by The International Continence as urgency, with or without urgency incontinence, usually with frequency and nocturia. There is lack of information why overactive bladder occurs, but it is known that it involves detrusor overactivity which is responsible for feeling urgency by involving afferent signaling conveyed as bladder sensations.
There are many options for treatment of overactive bladder such as; bladder training and drug therapy using anticholinergic substances such as propiverine hydrochloride and oxybutynin hydrochloride have been mostly used at present. However, intractable cases and side effects could be occurred such as urinary dysfunction and dry mouth and, therefore, Mirabegron has been reported as one of the substance for the management of overactive bladder.
Mirabegron is a selective agonist for human beta 3 -adrenoceptor (beta 3 -AR) which is also dominant in the human detrusor muscle. However, Mirabegron has been firstly declared by the Astellas Pharma Inc to be used for the treatment for diabetes, due to having an activity of promoting insulin secretion and enhancing insulin sensitivity, and also having an antiobestic activity and an antihyperlipemic activity. But then, it has been reported that Mirabegron can be used as an overactive bladder, such as overactive bladder accompanied by prostatic hyperplasia, or overactive bladder accompanied by urinary urgency, urinary incontinence, and urinary frequency.
The chemical name of Mirabegron is 2-(2-Amino-l,3-thiazoI-4-yl)-N-[4-(2-{[(2R)-2-hydroxy- 2-phenylethyl] amino} ethyl )phenyl] acetamide and the empirical formula is C2JH24N4O2S. The compound has a molecular weight of 396.506 g/mol. The structural formula of Mirabegron is shown in the Formula I.
Formula I
Mirabegron appears as a white crystalline powder and non-hygroscopic. It can freely soluble in dimethyl sulfoxide, soluble in methanol and soluble in water between neutral to acidic pH, thus it is categorized as BCS III Drug which means that Mirabegron exhibits high solubility and low permeability.
Mirabegron has one chiral center and exhibits stereoisomerism. The manufacture of the finish product consists of the R-enantiomer.
Mirabegron and its pharmaceutically acceptable salts thereof first have been described in EP1028111 numbered patent document by Yamanouchi Pharmaceutical Co. for the treatment of the Diabetes Mellitus. In particular, Example 41 discloses the preparation of mirabegron and its pharmaceutically acceptable salt thereof, with hydrochloride salt.
Moreover, patent document numbered as EP1559427 was first disclosed a pharmaceutical composition comprising mirabegron that can be used as a therapeutic agent for overactive bladder, such as overactive bladder accompanied by prostatic hyperplasia, or overactive bladder accompanied by urinary urgency, urinary incontinence, and urinary frequency.
Furthermore, the marketed product contains R-enantiomer of mirabegron was first described in patent document numbered as EP2298752, wherein an a-form crystal of mirabegron R- enantiomer has a moisture holding amount of not more than 0.2% and has main peaks at around 5.32, 8.08, 15.28, 17.88, 19.04, 20.20, 23.16 and 24.34 in the terms of 29(°) in the powder X- ray diffraction.
A pharmaceutical final product comprising mirabegron as an active was first approved in Japan and has been launched under the brand name of BETANIS®. In a similar way, it was commercially approved by the U.S. Food&Drug Administration in June 2012 and by European Medicines Agency in December 2012 and has been launched under the brand name of the MYRBETRIQ® in the United States and BETMIGA® in the Europe. All of the approved products are available as modified release tablet dosage form in the strength of 25 mg or 50 mg
of mirabegron for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Mirabegron is in the prolonged released film coated tablet dosage form to control the drug release from the tablet which lead to more slower absorption rate in the gastrointestinal tract than immediate release formulations, even in fasted conditions, due to pharmacokinetic variation of mirabegron according to the presence or absence of food intake. For instance, the rate of decrease in Cmax and AUC is 45% and 17%, respectively, when there is a coadministration with high fat meal. However, that decreasing is not higher when there is a coadministration with low fat meal which decreased Mirabegron Cmax and AUC by 75% and 51%, respectively.
In the state of art there are many patents/patent applications which are summarized below.
EP2554168 relates to a pharmaceutical composition for modified release comprising mirabegron or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein the dissolution rate of the drug from the composition is 75% or less after 1.5 hours from the beginning of the dissolution test, and also wherein the pharmaceutical composition is not a sustained release hydrogel formulation which contains an additive that allows water to penetrate into the formulation, and a hydrogel-forming polymer.
EP2345410 relates to a pharmaceutical composition for modified release comprising mirabegron, at least one additive having a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less to ensure penetration of water into the pharmaceutical composition, and a hydrogel-forming polymer having an average molecular weight of approximately 100.000 or more, or a viscosity of 12 mPa.s or more at a 5% aqueous solution at 25°C.
EP3278801 relates to a pharmaceutical composition comprising a complex of mirabegron with sodium polystyrene sulfonate, a thickener, and a hydrophobic substance, wherein the hydrophobic substance is magnesium stearate and/or calcium stearate.
EP2832730 relates to a pharmaceutical composition for modified release comprising mirabegron dodecyl sulfate wherein a molar ratio of Mirabegron to alkyl sulfuric acid is 1 : 1 to 1:2.
WO201 1122523 relates to a pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, and the drug dissolution rate after 30 minutes from the beginning of the dissolution test is less than 85%.
EP3345600 relates to a pharmaceutical composition comprising mirabegron, hypromellose, and polyvinylpyrrolidone, wherein the spray-dried granulated product contains 100% or more by mass of the hypromellose, and the polyvinylpyrrolidone in total with respect to a content of the mirabegron.
W02019072404 relates to a pharmaceutical composition for modified release comprising; mirabegron presenting 5-25 wt% to the total weight of the uncoated tablet, polyethylene oxide having an average molecular weight of approximately 7,000,000 or a viscosity of 7500 to 10000 cps at a 1% aqueous solution at 25°C and polyethylene glycol having an average molecular weight of approximately 6000 to 10000, preferably 8000, wherein the weight ratio polyethylene oxide to polyethylene glycol ranges from 1:3 to 1:4.5;
EP3448366 relates to a pharmaceutical composition for modified release comprising; 5 to 25 wt%, relative to the total weight of mirabegron, 15 to 40 wt%, relative to the total weight, of a mixture of one or more polyethylene oxides having a viscosity of 100 to 800, preferably 400 to 800 cP at a 2% aqueous solution at 25°C, and a water insoluble hydrophilic excipient.
EP3554480 relates to a solid prolonged release solid pharmaceutical oral dosage form comprising mirabegron or a pharmaceutically acceptable salt thereof wherein Mirabegron is distributed in a sustained release matrix comprising a hydrogel generator selected from the group consisting of a mixture of at least two different hydroxypropyl methylcellulose, of alginate, alginic acid, poly (meth) acrylate -based polymer and carrageenan, and wherein dissolution rate of the drug from the composition is 20% to 40% in 3 hours, 44% to 64% in 5 hours and more than 80% in 8.5 h.
WO2018169325 relates to a controlled release pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof and a polyethylene oxide as a sustained release agent.
Although there are many patent applications of various patent applications, there is a need to develop a pharmaceutical composition comprising mirabegron that capable of avoiding the
effects of food intake with a prolonged release based on a functional film coating including hydrophobic polymer and a plasticizer.
In the present invention, the prepared pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient in a prolonged release profile by using a hydrophobic polymer with a plasticizer in a range ratio of 1:0.5 - 1:1 in the film coating layer.
SUMMARY OF THE INVENTION
The object of this invention is to develop a prolonged release solid pharmaceutical composition comprising a therapeutically effective amount of mirabegron or one of its pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient.
It is an object of the present invention is to develop a prolonged release solid pharmaceutical composition comprising mirabegron or one of its pharmaceutically acceptable salts, which is used in the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The present invention is to develop a prolonged release solid composition comprising mirabegron and at least one pharmaceutically acceptable excipient manufactured by using wet granulation process.
Another object of the present invention is to develop preparation method of a pharmaceutical composition of Mirabegron wherein the pharmaceutical compositions herein disclosed can be manufactured into solid dosage forms, such as tablet, capsule, granule, powder.
Another object of the present invention is related to a pharmaceutical composition comprising mirabegron and at least one pharmaceutically acceptable excipient and a functional film coating including a hydrophobic polymer and a plasticizer.
Another object of the present invention relates to a pharmaceutical composition comprising a hydrophobic polymer and a plasticizer in a range ratio of 1:0.5 - 1:1 in the coating film layer to provide prolonged release of mirabegron throughout the entire gastrointestinal tract.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient.
Mirabegron is a human P3 -adrenoceptor agonist which has been used for the management of overactive bladder syndrome for decades. Mirabegron exhibits high solubility and low permeability. Thus, after oral administration it is rapidly absorbed, but its absolute bioavailability is low and it slightly increased 29% at a 25 mg dose and 35% at a 50 mg dose. Besides that, there is another restriction about its bioavailability when given with food or absence of food throughout gastrointestinal tract.
Therefore, in the present invention relates to a pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof, wherein the variation in bioavailability caused by the presence or absence of food intake throughout gastrointestinal tract is minimized by controlling the drug release. The composition comprising mirabegron or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient is presented as prolonged release tablet dosage form.
The term "prolonged release" herein refers to any composition or dosage form which comprises active ingredient and which is formulated to provide a longer duration of pharmacological response after administration of the dosage form than is ordinarily experienced after administration of a corresponding immediate release composition comprising the same drug in the same amount. Prolonged release is a continuous release of the active ingredient in a period of time of greater than about 1 hour, preferably greater than about 4 hours, more preferably, greater than about 8 hours. The term “prolonged release” can be conveniently replaced by similar terms like modified release, controlled release, timed release, retarded release, extended release and delayed release, sustained release, programmed release and/or rate controlled dosage forms.
In a preferred embodiment of the present invention is to provide a pharmaceutical composition for oral administration. Suitable solid oral dosage forms are selected from the group comprising tablet, capsule, granule, powder, preferably the solid oral dosage form is tablet.
In a preferred embodiment of prolonged release solid dosage composition, a hydrophobic polymer is designated for continuous drug release in the human gastrointestinal tract with diffusion of dissolving drug through a network of channels that exist between compacted polymer particles.
In the preferred embodiment of the present invention, the hydrophobic polymer may include, but are not limited to, polyethylene, polyvinyl chloride, ethyl cellulose and acrylate polymers and their copolymers. Preferably, the hydrophobic polymer is selected as ethyl cellulose.
In the development dosage forms with modified release, ethyl cellulose is the perfect polymer to ensure drug dissolution throughout gastrointestinal tract and provide constant drug concentration. As the mechanism of action of ethyl cellulose, being insoluble at any gastrointestinal fluid at any pH, it undergoes to swell in these environments. As a result, it plays a significant role to improve the therapeutic effectiveness. In the present invention, it is used to provide the release of a drug in a controlled manner by using as an agent in coating formulation.
Ethyl cellulose is a biocompatible, non-allergenic, nonirritant, colorless, odorless, and tasteless hydrophobic polymer soluble in a wide variety of organic solvents such as alcohols, ketones, and polycyclic aromatic hydrocarbons, or solvent mixture to produce water insoluble films, but it does not dissolve in water, glycerin, or propylene glycol.
Ethyl cellulose effect can be modified by using in combination with a proper plasticizer in a specific ratio. Moreover, wherein plasticizer molecules are built in amongst the polymer chains that may cause to shift along each other in order to increasing the elasticity of the polymer film.
The compatibility between the excipients is quite important in order to reduce potential reduction between excipients which may affect the chemical, physical, bioavailability and stability of the dosage form. According to the literature knowledge, ethyl cellulose is known to be quite compatible polymer with a wide array of excipients and most of the plasticizer. Thus, in the preferred embodiment of the present invention, the plasticizer may include, but are not limited triethyl citrate, acetyltriethyl citrate, tributyl citrate, and acetyltributyl citrate and the like and mixtures thereof. Preferably, the plasticizer is selected as triethyl citrate.
In one of the preferred embodiment of the present invention is to provide a pharmaceutical compositions comprising Mirabegron by using wet granulation process wherein provided for the manufacture of tablets containing the active ingredient, hydrophobic polymer binder, antioxidant, plasticizer, glidant and lubricant and solvent selected as to be the most suitable ones with respect to the intended form of administration.
In the preferred embodiment of the present invention, the binder may include, but are not limited to dibasic calcium phosphate dihydrate, polysaccharides, microcrystalline cellulose, lactose and the like and mixtures thereof. Preferably, the binder is microcrystalline cellulose.
In the preferred embodiment of the present invention, the antioxidant may include, but are not limited to butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate, sodium sulfite, sodium thiosulfate, monothioglycerol, tert-butyl hydroquinone, ethoxyquin, dithiothreitol, and derivatives thereof. Preferably, the antioxidant is butylated hydroxy toluene.
In the preferred embodiment of the present invention, the lubricant may include, but are not limited to magnesium stearate, zinc stearate, calcium stearate, talc, carnauba wax, stearic acid, sodium stearyl fumarate sodium laurel sulfate, glyceryl palmitostearate, and hydrogenated vegetable oils and fats, as well as other known lubricants. Preferably, the lubricant is magnesium stearate.
In the preferred embodiment of the present invention, the glidant may include, but are not limited to silicon dioxide, colloidal silicon dioxide, magnesium silicate, magnesium trisilicate, talc and other known glidant. Preferably, the glidant is colloidal silicon dioxide.
In the preferred embodiment of the present invention, the solvent may include, but are not limited deionized water, methanol, ethanol, isopropyl alcohol, dichloromethane, acetone, ethyl acetate, dimethylsulfoxide and their mixtures thereof. Preferably, the solvent is deionized water.
The embodiment in accordance with the present invention was designed with adjusted quantitative composition composed of pharmaceutically acceptable ingredients mentioned above by using wet granulation process.
The embodiment identified as Example 1 was given in the Table- 1 below.
The proposed embodiment based on the invention provides a prolonged release solid pharmaceutical composition is as stated below:
Another object of the present invention relates to provide wet granulation process for preparing a prolonged release pharmaceutical composition, providing the steps of:
i. Mirabegron, Microcrystalline cellulose and Butylated hydroxytoluene were screened through a proper sieve and transferred into high-shear mixer and stirred, ii. Ethyl cellulose was dissolved in sufficient quantity of deionized water and added to the preparation in Step i to perform granulation process, iii. The granules prepared in Step ii were dried in fluid bed dryer and shifted through a proper sieve, iv. Colloidal silicon dioxide was screened through a proper sieve and added to the granules prepared in Step iii and stirred, v. Magnesium stearate was screened through a proper sieve and added to the granules prepared in Step iv and stirred to obtain a uniform final blend, vi. Tablet compression was performed with the final blend in Step v. vii. The coating was formulated separately including 1:0.5 - 1:1 ratio of ethyl cellulose and triethyl citrate, then it was applied to tablets prepared in Step vi.
The coating film layer is applied after the core tablet is prepared by using wet granulation process wherein the coating consists of ethyl cellulose as a hydrophobic polymer which is insoluble in water and gastro-intestinal fluids and triethyl citrate as a plasticizer in the ratio of
1:0.5 - 1:1 by weight.
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.
Claims
1. A prolonged release solid pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable excipient and a film coating layer comprising hydrophobic polymer and a plasticizer, wherein the weight ratio of hydrophobic polymer to plasticizer is between 1:0.5 - 1:1.
2. A prolonged release solid pharmaceutical composition according to Claim 1, wherein the hydrophobic polymer is selected from polyethylene, polyvinyl chloride, ethyl cellulose, acrylate polymers and their copolymers.
3. A prolonged release solid pharmaceutical composition according to claims 1 or 2, wherein the hydrophobic polymer is ethyl cellulose.
4. A prolonged release solid pharmaceutical composition according to any one of the preceding claims, wherein the plasticizer is selected from triethyl citrate, acetyltriethyl citrate, tributyl citrate, acetyltributyl citrate and mixtures thereof.
5. A prolonged release solid pharmaceutical composition according to any one of the preceding claims, wherein the plasticizer is triethyl citrate.
6. A prolonged release solid pharmaceutical composition according to Claim 1, wherein at least one pharmaceutically acceptable excipient is selected from filler, disintegrant, glidant, surfactant, lubricant and mixtures thereof.
7. A prolonged release solid pharmaceutical composition according to any one of the preceding claims, wherein the composition is prepared by wet granulation method.
8. A prolonged release solid pharmaceutical composition according to any one of the preceding claims for use in the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2020/051260 WO2022125007A1 (en) | 2020-12-08 | 2020-12-08 | Prolonged release mirabegron formulations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2020/051260 WO2022125007A1 (en) | 2020-12-08 | 2020-12-08 | Prolonged release mirabegron formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022125007A1 true WO2022125007A1 (en) | 2022-06-16 |
Family
ID=81974491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2020/051260 WO2022125007A1 (en) | 2020-12-08 | 2020-12-08 | Prolonged release mirabegron formulations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022125007A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1025848A1 (en) * | 1997-09-30 | 2000-08-09 | Nikken Chemicals Company, Limited | Sustained-release theophylline tablet |
EP2832730A1 (en) * | 2012-03-30 | 2015-02-04 | Astellas Pharma Inc. | Mirabegron-containing pharmaceutical composition |
-
2020
- 2020-12-08 WO PCT/TR2020/051260 patent/WO2022125007A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1025848A1 (en) * | 1997-09-30 | 2000-08-09 | Nikken Chemicals Company, Limited | Sustained-release theophylline tablet |
EP2832730A1 (en) * | 2012-03-30 | 2015-02-04 | Astellas Pharma Inc. | Mirabegron-containing pharmaceutical composition |
Non-Patent Citations (4)
Title |
---|
ADELEKE, O. A.: "Premium ethylcellulose polymer based architectures at work in drug delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS: X, 1, 100023, 2019, XP055951914 * |
AGRAWAL, A. M. ET AL.: "Wet granulation fine particle ethylcellulose tablets: effect of production variables and mathematical modeling of drug release", AAPS PHARMSCI, vol. 5, no. 2, 2003, pages 48 - 60, XP035718641, DOI: 10.1208/ps050213 * |
DASHEVSKY, A. ET AL.: "Compression of pellets coated with various aqueous polymer dispersions", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 279, no. 1-2, 2004, pages 19 - 26, XP055951911 * |
HUNG, S. F. ET AL.: "Characterizations of plasticized polymeric film coatings for preparing multiple-unit floating drug delivery systems (muFDDSs) with controlled-release characteristics", PLOS ONE, vol. 9, no. 6, 2014, XP055951912 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9180101B2 (en) | Pharmaceutical composition simultaneously having rapid-acting property and long-acting property | |
US5266331A (en) | Controlled release oxycodone compositions | |
JP5816091B2 (en) | Sodium oxybate immediate release dosage form | |
CA2652712C (en) | Stabilized pharmaceutical compositions comprising fesoterodine | |
US8778397B2 (en) | Stabilized tolterodine tartrate formulations | |
RU2572695C2 (en) | Application of binding agents to obtain stable in storage compositions | |
JPH11505542A (en) | Triphasic pharmaceutical formulation with constant and controlled release of amorphous active ingredient for once daily dosing | |
KR100678421B1 (en) | Controlled-release formulation containing tamsulosin hydrochloride | |
CA2555295C (en) | Extended release coated mini-tablets of venlafaxine hydrochloride | |
US20160287541A1 (en) | Modified Release Tranexamic Acid Formulation | |
BG107372A (en) | Sustained-release preparations of quinolone antibiotics and method for preparation thereof | |
KR20190064215A (en) | Pharmaceutical Composition Comprising Tofacitinib | |
WO2022125007A1 (en) | Prolonged release mirabegron formulations | |
WO2014096982A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
WO2008032208A2 (en) | Extended release formulation of an antiepileptic agent | |
KR20210012082A (en) | A pharmaceutical composition comprising mirabegron and tamsulosin | |
WO2014096983A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
TR2023006080T2 (en) | EXTENDED RELEASE MIRABEGRON FORMULATIONS | |
WO2023113706A1 (en) | Pharmaceutical composition comprising mirabegron in matrix form | |
IE883894L (en) | Synergistic combination of decarboxylase inhibitors and L-dopa pellets | |
WO2023080855A1 (en) | Pharmaceutical composition comprising mirabegron and calcium salts | |
KR20160141044A (en) | Extended Release Formulation for Oral Administration of Sildenafil | |
WO2010112221A1 (en) | Pharmaceutical compositions comprising memantine | |
WO2006136927A1 (en) | Extended release formulations comprising venlafaxine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20965251 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20965251 Country of ref document: EP Kind code of ref document: A1 |